Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bicara Therapeutics Inc. (BCAX:NASDAQ), powered by AI.
Bicara Therapeutics Inc. is currently trading at $21.69. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bicara Therapeutics Inc. on Alpha Lenz.
Bicara Therapeutics Inc.'s P/E ratio is -8.6.
“Bicara Therapeutics Inc. trades at a P/E of -8.6 (undervalued) with modest ROE of -30.9%.”
Ask for details →Bicara Therapeutics Inc. is a biotechnology company focused on the development of innovative therapies for cancer treatment. The company primarily aims to enhance the effectiveness of immunotherapies by using multi-functional antibodies that modulate the tumor microenvironment. These pioneering therapies are designed to target complex and challenging cancers, potentially offering patients new avenues for treatment. Bicara Therapeutics operates within the rapidly growing biotechnology sector, where advancements in immuno-oncology and personalized medicine are significantly impacting cancer treatment protocols. The company's efforts contribute to a larger industry shift towards more targeted and effective biologic drugs, aiming to improve efficacy while reducing adverse effects commonly associated with conventional cancer treatments. Headquartered in the United States, Bicara Therapeutics plays an essential role in advancing cancer research and therapy by pushing the boundaries of current medical technologies in oncology.
“Bicara Therapeutics Inc. trades at a P/E of -8.6 (undervalued) with modest ROE of -30.9%.”
Ask for details →Bicara Therapeutics Inc. (ticker: BCAX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 55 employees. Market cap is $1.2B.
The current price is $21.69 with a P/E ratio of -8.6x and P/B of 2.95x.
ROE is -30.88%.